We are live on ! Find out more
GC

Grimes & Company Portfolio holdings

AUM $4.62B
1-Year Est. Return 29.71%
This Fund
S&P 500
This Quarter Est. Return
+0.62%
1 Year Est. Return
+29.71%
3 Year Est. Return
+66.17%
5 Year Est. Return
+73.59%
10 Year Est. Return
+287.63%
AUM
$3.34B
AUM Growth
+$88.5M
Cap. Flow
+$90.4M
Cap. Flow %
2.71%
Top 10 Hldgs %
44.68%
Holding
363
New
18
Increased
199
Reduced
111
Closed
14
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARCC icon
326
Ares Capital
ARCC
$13.5B
$206K 0.01%
+9,897
New +$207K
PH icon
327
Parker-Hannifin
PH
$123B
$206K 0.01%
408
+27
+7% +$14.5K
JCI icon
328
Johnson Controls International
JCI
$88.8B
$205K 0.01%
3,089
+27
+0.9% +$1.82K
SHY icon
329
iShares 1-3 Year Treasury Bond ETF
SHY
$25.5B
$203K 0.01%
2,484
+24
+1% +$1.95K
LNC icon
330
Lincoln National
LNC
$8.73B
$203K 0.01%
6,514
-53
-0.8% -$1.6K
DGRW icon
331
WisdomTree Trust WisdomTree US Quality Dividend Growth Fund
DGRW
$16.7B
$202K 0.01%
+2,593
New +$196K
INVA icon
332
Innoviva
INVA
$1.55B
$195K 0.01%
11,897
+83
+0.7% +$1.29K
CRF
333
Cornerstone Total Return Fund
CRF
$1.16B
$185K 0.01%
23,999
+948
+4% +$7.05K
HBAN icon
334
Huntington Bancshares
HBAN
$34.4B
$169K 0.01%
12,818
+83
+0.7% +$1.12K
HRTX icon
335
Heron Therapeutics
HRTX
$93.9M
$168K 0.01%
47,863
+893
+2% +$2.74K
CLM icon
336
Cornerstone Strategic Value Fund
CLM
$2.22B
$165K ﹤0.01%
21,738
+909
+4% +$6.73K
VLY icon
337
Valley National Bancorp
VLY
$7.9B
$101K ﹤0.01%
14,500
NAK
338
Northern Dynasty Minerals
NAK
$784M
$92.8K ﹤0.01%
298,950
AINC
339
DELISTED
Ashford Inc.
AINC
$83.7K ﹤0.01%
+17,044
New +$81.6K
IBRX icon
340
ImmunityBio
IBRX
$7.51B
$63.2K ﹤0.01%
10,000
EOSE icon
341
Eos Energy Enterprises
EOSE
$1.22B
$50.8K ﹤0.01%
40,000
MRNS
342
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$39.3K ﹤0.01%
33,609
+60
+0.2% +$150
RBBN icon
343
Ribbon Communications
RBBN
$377M
$33K ﹤0.01%
10,030
MRSN
344
DELISTED
Mersana Therapeutics
MRSN
$30.1K ﹤0.01%
600
-14
-2% -$1.01K
REKR icon
345
Rekor Systems
REKR
$85.8M
$25.6K ﹤0.01%
16,500
RGLS
346
DELISTED
Regulus Therapeutics
RGLS
$19.6K ﹤0.01%
10,975
+711
+7% +$1.65K
VOR icon
347
Vor Biopharma
VOR
$1.15B
$15.1K ﹤0.01%
757
+51
+7% +$1.65K
FUBO icon
348
FuboTV Inc
FUBO
$261M
$12.4K ﹤0.01%
833
ISPC icon
349
iSpecimen
ISPC
$2.72M
$9.52K ﹤0.01%
39
ADSK icon
350
Autodesk
ADSK
$49.5B
-780
Closed -$203K

Similar funds

Grimes & Company's Q2 2024 Portfolio in Review

As of Q2 2024, Grimes & Company held 363 positions worth $3.34B, up 2.7% from $3.25B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Grimes & Company's Q2 2024 filing shows 18 new, 199 increased, 111 reduced and 14 closed positions. Its largest new stake was McCormick & Company Non-Voting: 80,978 shares worth $5.74M. The largest sale was State Street Industrial Select Sector SPDR ETF, an estimated $21.7M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

  • Grimes & Company's largest Q2 2024 buy was McCormick & Company Non-Voting: 80,978 shares worth $5.74M.
  • Grimes & Company added most to iShares Core MSCI Emerging Markets ETF in Q2 2024, an estimated $32.9M increase.
  • Grimes & Company's biggest Q2 2024 reduction was State Street Consumer Staples Select Sector SPDR ETF, cutting an estimated $20.9M.
  • Grimes & Company fully exited State Street Industrial Select Sector SPDR ETF in Q2 2024, selling an estimated $21.7M.
  • Grimes & Company's ten largest holdings make up 45% of its $3.34B portfolio in Q2 2024.
  • Grimes & Company opened 18 new positions and closed 14 in Q2 2024.
  • Grimes & Company's portfolio value rose 2.7% quarter-over-quarter to $3.34B.

Based on Grimes & Company's 13F filing for Q2 2024, filed 22 Jul 2024.